Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
243 studies found for:    Ankylosing Spondylitis
Show Display Options
Rank Status Study
21 Completed
Has Results
Study Evaluating Predictors of Response in Patients With Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention: Other: Treatment switching
22 Terminated
Has Results
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs
Condition: Spondylitis, Ankylosing
Interventions: Biological: tocilizumab;   Drug: Placebo
23 Completed
Has Results
A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis
Condition: Spondylitis, Ankylosing
Interventions: Biological: golimumab;   Biological: Golimumab (CNTO 148); placebo
24 Completed
Has Results
Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab
Conditions: Rheumatoid Arthritis;   Ankylosing Spondylitis;   Psoriatic Arthritis
Intervention:
25 Completed
Has Results
EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries
Conditions: Ankylosing Spondylitis (AS);   Psoriatic Arthritis (PsA;   Rheumatoid Arthritis (RA
Intervention:
26 Completed Resistance Training Exercise Using the Swiss Ball in Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Interventions: Other: Exercise;   Other: Drug treatment
27 Unknown  Etanercept (Enbrel) in Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention: Drug: Etanercept
28 Completed
Has Results
Extension Study Evaluating Etanercept in Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention: Drug: Enbrel (etanercept)
29 Active, not recruiting 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Interventions: Drug: Secukinumab (75 mg);   Drug: Secukinumab (150 mg);   Drug: Placebo
30 Completed
Has Results
Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Interventions: Drug: Celecoxib;   Drug: Diclofenac SR
31 Active, not recruiting Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)
Condition: Ankylosing Spondylitis
Intervention:
32 Completed Ultrasound of Enthesis in Patients With Ankylosing Spondylitis: a Comparative Study With Health Subjects
Condition: Spondylitis, Ankylosing
Intervention:
33 Recruiting Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)
Condition: Ankylosing Spondylitis
Interventions: Drug: Adalimumab;   Drug: Methotrexate
34 Active, not recruiting Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis
Condition: Ankylosing Spondyloarthritis
Interventions: Drug: Apremilast tablet 20 mg;   Drug: Apremilast tablet 30 mg BID;   Drug: Placebo
35 Recruiting Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy
Condition: Ankylosing Spondylitis
Intervention: Other: no intervention
36 Recruiting Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
Conditions: Rheumatoid Arthritis;   Ankylosing Spondylitis;   Psoriatic Arthritis;   Crohn´s Disease;   Ulcerative Colitis;   Plaque Psoriasis
Intervention:
37 Active, not recruiting A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Conditions: Rheumatoid Arthritis;   Psoriatic Arthritis;   Ankylosing Spondylitis
Intervention:
38 Completed
Has Results
Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care
Conditions: Rheumatoid Arthritis;   Psoriatic Arthritis;   Ankylosing Spondylitis
Intervention:
39 Recruiting Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium
Conditions: Ankylosing Spondylitis;   Psoriatic Arthritis
Intervention:
40 Completed Genetic Determinants of Ankylosing Spondylitis Severity
Condition: Ankylosing Spondylitis
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years